Ketamine Infusion for Comorbid PTSD and Chronic Pain
Source: ClinicalTrials.gov NCT04322968 ↗No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Impact of Event Scale-Revised (IES-R) |
28.22; 33.66666667; 11.44; 13.41 | — |
| PRIMARY Visual Analogue Scale (VAS) |
48.22; 52.88; 43.33; 48.23 | — |
| SECONDARY Impact of Event Scale-Revised (IES-R) |
28.22; 33.66666667; 11.44; 13.41 | — |
| SECONDARY Visual Analogue Scale (VAS) |
48.22; 52.88; 43.33; 48.23 | — |
| SECONDARY Brief Pain Inventory (Short Form) |
38.62; 25.66; 9.62; 28.33; 20.75; 14.66 | — |
Eligibility Criteria
Inclusion Criteria
Veterans with chronic pain as defined by having any chronic pain beyond 6 months in duration with and without PTSD diagnoses (participants must meet DSM-V criteria for current post-traumatic stress disorder (PTSD) and have received a diagnosis of PTSD greater than or equal to 3 months prior to assessment); they also will be either free of concomitant use of psychotropic and/or pain medications for at least 6 weeks or on stable doses of those medications within the last 6 weeks prior to randomization and for the duration of the study; if applicable, current frequency and duration of psychotherapy sessions must remain stable for at least 6 weeks prior to beginning of the study.
Exclusion Criteria
Inability to speak English, inability or unwillingness to provide written informed consent; moderate-to-severe cognitive impairment (Mini-Mental State Examination scores<20 administered by a trained clinician); current or lifetime history of psychotic or bipolar disorder; current bulimia or anorexia nervosa, alcohol abuse or dependence in the previous 3 months; serious unstable medical illness or sleep apnea; HTN, prolonged QT interval, peptic ulcer disease or recent history of GI-bleed, renal insufficiency, active substance use disorder, active suicidal or homicidal ideation on presentation; pregnancy (confirmed by baseline lab test), the initiation of female hormonal treatments within 3 months of screening, or inability or unwillingness to use a medically accepted contraceptive method for the duration of the study.
Data sourced from ClinicalTrials.gov (NCT04322968). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.